stock-detail (KPTI)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

4/23/2017 12:18 pm

4/23/2017 12:18 pm

4/23/2017 12:18 pm

4/23/2017 12:18 pm

4/23/2017 12:18 pm

4/19/2017 06:18 pm

4/19/2017 06:18 pm

4/19/2017 06:18 pm

4/19/2017 06:18 pm

4/19/2017 06:18 pm

4/12/2017 06:17 am

4/12/2017 06:17 am

4/12/2017 06:17 am

4/12/2017 06:17 am

4/12/2017 06:17 am

4/7/2017 06:17 am

4/7/2017 06:17 am

4/7/2017 06:17 am

4/7/2017 06:17 am

4/7/2017 06:17 am

Karyopharm Announces Management Change

4/3/2017 08:00 pm

[GlobeNewswire] - NEWTON, Mass., April 03, 2017-- Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, today announced that Justin Renz, Executive Vice President, Chief Financial Officer and Treasurer, ...

Karyopharm to Present Selinexor Phase 2b SADAL Data at the American Association for Cancer Research Annual Meeting 2017

3/31/2017 08:02 pm

[GlobeNewswire] - Abstract Published Today Highlighting Interim Phase 2 b SADAL Results in Patients with Relapsed or Refractory DLBCL. Overall Response Rate Greater Than 28%, along with Additional Updated Data, to Be Presented ...

U.S. FDA Division of Hematology Products Lifts Partial Clinical Hold on Karyopharm’s Selinexor Clinical Trials

3/30/2017 11:00 am

[GlobeNewswire] - Recruitment Resumes Across All Selinexor Trials in Hematological Malignancies. Timelines for Ongoing and Planned Studies Expected to Remain Materially Unchanged. NEWTON, Mass., March 30, 2017-- Karyopharm ...